Pliant Therapeutics Announces Positive Safety and Efficacy

PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatmentPLN-74809 treatment effect was observed on...

Related Keywords

,Lisah Lancaster ,Vanderbilt School Of Medicine ,Linkedin ,Twitter ,Pliant Therapeutics Inc ,Drug Administration ,Nasdaq ,Novartis ,Youtube ,Facebook ,European Medicines Agency ,Monday July ,Quantitative Lung Fibrosis ,Well Tolerated Across All ,Dose Dependent Treatment Effects ,Mixed Model Repeat Measures Analysis ,Chief Medical Offer ,Vanderbilt School ,Forced Vital Capacity ,Idiopathic Pulmonary ,Pliant Therapeutics ,Fast Track Designation ,Orphan Drug Designation ,